Gilead Historical Balance Sheet

0QYQ Stock

92.82 0.27 0.29%

Trend analysis of Gilead Sciences balance sheet accounts such as Short Long Term Debt Total of 21.2 B, Total Current Liabilities of 12.1 B or Total Stockholder Equity of 16.6 B provides information on Gilead Sciences' total assets, liabilities, and equity, which is the actual value of Gilead Sciences to its prevalent stockholders. By breaking down trends over time using Gilead Sciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Gilead Sciences Inventory

1.35 Billion

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gilead Stock please use our How to Invest in Gilead Sciences guide.

About Gilead Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Gilead Sciences at a specified time, usually calculated after every quarter, six months, or one year. Gilead Sciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Gilead Sciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Gilead currently owns. An asset can also be divided into two categories, current and non-current.

Gilead Sciences Balance Sheet Chart

At this time, Gilead Sciences' Cash is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 19.1 B in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 21.2 B in 2024.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity

Total Assets

Total assets refers to the total amount of Gilead Sciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Gilead Sciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Gilead Sciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Gilead Sciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Gilead Sciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gilead Stock please use our How to Invest in Gilead Sciences guide.At this time, Gilead Sciences' Cash is comparatively stable compared to the past year. Total Current Assets is likely to gain to about 19.1 B in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 21.2 B in 2024.

	2020	2023	2024 (projected)
Short and Long Term Debt Total	28.6B	25.8B	21.2B
Total Assets	68.4B	78.1B	73.0B

Short Long Term Debt Total Total Assets

Gilead Sciences balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Other Liab	Net Tangible Assets	Accounts Payable
Total Assets		0.22	0.98	-0.65	-0.44	-0.63	0.29	0.22	-0.35	0.59	0.35	-0.14	0.03	0.28	-0.08	-0.55	0.93	-0.34	0.41	-0.53	0.13	0.27	0.28	-0.25	0.7
Short Long Term Debt Total	0.22		0.27	0.22	0.45	-0.5	-0.28	1.0	0.37	-0.2	-0.27	0.56	-0.57	-0.36	-0.63	-0.64	0.48	0.31	-0.19	0.64	-0.62	-0.25	-0.26	0.27	-0.19
Total Current Liabilities	0.98	0.27		-0.67	-0.47	-0.61	0.2	0.27	-0.4	0.6	0.4	-0.19	0.05	0.33	-0.01	-0.52	0.94	-0.38	0.47	-0.5	0.13	0.38	0.39	-0.35	0.64
Total Stockholder Equity	-0.65	0.22	-0.67		0.73	0.42	0.2	0.22	0.57	-0.58	-0.4	0.45	-0.23	-0.45	0.03	0.46	-0.65	0.46	-0.43	0.78	-0.3	-0.34	-0.61	0.54	-0.55
Retained Earnings	-0.44	0.45	-0.47	0.73		0.3	-0.02	0.45	0.96	-0.92	-0.9	0.93	-0.82	-0.93	-0.51	0.01	-0.34	0.92	-0.89	0.67	-0.85	-0.81	-0.84	0.92	-0.68
Cash	-0.63	-0.5	-0.61	0.42	0.3		-0.03	-0.5	0.38	-0.51	-0.29	0.07	0.01	-0.27	0.47	0.7	-0.75	0.38	-0.35	0.09	-0.04	-0.25	-0.3	0.31	-0.24
Other Assets	0.29	-0.28	0.2	0.2	-0.02	-0.03		-0.28	-0.1	0.17	0.13	-0.07	0.15	0.05	0.39	0.38	-0.02	-0.15	0.09	-0.35	0.26	0.16	-0.21	0.13	0.25
Long Term Debt	0.22	1.0	0.27	0.22	0.45	-0.5	-0.28		0.37	-0.2	-0.27	0.56	-0.57	-0.36	-0.63	-0.64	0.48	0.31	-0.19	0.64	-0.62	-0.25	-0.26	0.27	-0.19
Cash And Short Term Investments	-0.35	0.37	-0.4	0.57	0.96	0.38	-0.1	0.37		-0.92	-0.94	0.95	-0.86	-0.96	-0.53	-0.08	-0.26	0.99	-0.93	0.54	-0.89	-0.9	-0.85	0.96	-0.54
Net Receivables	0.59	-0.2	0.6	-0.58	-0.92	-0.51	0.17	-0.2	-0.92		0.94	-0.82	0.79	0.92	0.4	-0.14	0.5	-0.94	0.95	-0.49	0.82	0.8	0.74	-0.86	0.76
Good Will	0.35	-0.27	0.4	-0.4	-0.9	-0.29	0.13	-0.27	-0.94	0.94		-0.92	0.91	0.98	0.62	0.13	0.25	-0.98	0.99	-0.36	0.91	0.91	0.8	-0.93	0.62
Short Term Investments	-0.14	0.56	-0.19	0.45	0.93	0.07	-0.07	0.56	0.95	-0.82	-0.92		-0.95	-0.96	-0.72	-0.32	-0.01	0.94	-0.89	0.51	-0.95	-0.88	-0.82	0.93	-0.5
Capital Surpluse	0.03	-0.57	0.05	-0.23	-0.82	0.01	0.15	-0.57	-0.86	0.79	0.91	-0.95		0.94	0.74	0.43	-0.12	-0.9	0.87	-0.34	0.99	0.82	0.71	-0.84	0.47
Inventory	0.28	-0.36	0.33	-0.45	-0.93	-0.27	0.05	-0.36	-0.96	0.92	0.98	-0.96	0.94		0.6	0.16	0.19	-0.98	0.97	-0.41	0.93	0.91	0.86	-0.96	0.55
Other Current Assets	-0.08	-0.63	-0.01	0.03	-0.51	0.47	0.39	-0.63	-0.53	0.4	0.62	-0.72	0.74	0.6		0.77	-0.33	-0.56	0.57	-0.36	0.74	0.68	0.42	-0.52	0.3
Other Stockholder Equity	-0.55	-0.64	-0.52	0.46	0.01	0.7	0.38	-0.64	-0.08	-0.14	0.13	-0.32	0.43	0.16	0.77		-0.77	-0.11	0.05	-0.04	0.39	0.29	0.08	-0.07	-0.28
Total Liab	0.93	0.48	0.94	-0.65	-0.34	-0.75	-0.02	0.48	-0.26	0.5	0.25	-0.01	-0.12	0.19	-0.33	-0.77		-0.24	0.33	-0.31	-0.06	0.18	0.28	-0.24	0.55
Total Current Assets	-0.34	0.31	-0.38	0.46	0.92	0.38	-0.15	0.31	0.99	-0.94	-0.98	0.94	-0.9	-0.98	-0.56	-0.11	-0.24		-0.97	0.44	-0.91	-0.92	-0.82	0.95	-0.56
Intangible Assets	0.41	-0.19	0.47	-0.43	-0.89	-0.35	0.09	-0.19	-0.93	0.95	0.99	-0.89	0.87	0.97	0.57	0.05	0.33	-0.97		-0.34	0.86	0.91	0.8	-0.93	0.63
Common Stock	-0.53	0.64	-0.5	0.78	0.67	0.09	-0.35	0.64	0.54	-0.49	-0.36	0.51	-0.34	-0.41	-0.36	-0.04	-0.31	0.44	-0.34		-0.47	-0.36	-0.42	0.39	-0.54
Property Plant Equipment	0.13	-0.62	0.13	-0.3	-0.85	-0.04	0.26	-0.62	-0.89	0.82	0.91	-0.95	0.99	0.93	0.74	0.39	-0.06	-0.91	0.86	-0.47		0.81	0.68	-0.82	0.55
Other Current Liab	0.27	-0.25	0.38	-0.34	-0.81	-0.25	0.16	-0.25	-0.9	0.8	0.91	-0.88	0.82	0.91	0.68	0.29	0.18	-0.92	0.91	-0.36	0.81		0.87	-0.92	0.34
Other Liab	0.28	-0.26	0.39	-0.61	-0.84	-0.3	-0.21	-0.26	-0.85	0.74	0.8	-0.82	0.71	0.86	0.42	0.08	0.28	-0.82	0.8	-0.42	0.68	0.87		-0.92	0.26
Net Tangible Assets	-0.25	0.27	-0.35	0.54	0.92	0.31	0.13	0.27	0.96	-0.86	-0.93	0.93	-0.84	-0.96	-0.52	-0.07	-0.24	0.95	-0.93	0.39	-0.82	-0.92	-0.92		-0.44
Accounts Payable	0.7	-0.19	0.64	-0.55	-0.68	-0.24	0.25	-0.19	-0.54	0.76	0.62	-0.5	0.47	0.55	0.3	-0.28	0.55	-0.56	0.63	-0.54	0.55	0.34	0.26	-0.44

Click cells to compare fundamentals

Gilead Sciences Account Relationship Matchups

Gilead Sciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	63.7B	61.6B	68.4B	68.0B	78.1B	73.0B
Total Current Liabilities	9.8B	11.4B	11.6B	11.2B	12.9B	12.1B
Total Stockholder Equity	21.4B	22.5B	18.2B	21.1B	19.0B	16.6B
Retained Earnings	19.4B	14.4B	16.3B	15.7B	14.1B	13.8B
Cash	17.9B	11.6B	6.0B	7.8B	7.0B	8.2B
Other Assets	3.1B	1.7B	2.9B	2.9B	3.4B	2.9B
Cash And Short Term Investments	30.1B	24.4B	7.4B	7.8B	7.0B	6.7B
Net Receivables	3.6B	4.9B	4.5B	4.8B	5.5B	4.6B
Inventory	922M	1.7B	1.6B	1.5B	1.7B	1.3B
Other Stockholder Equity	85M	(60M)	83M	2M	2.3M	2.2M
Total Liab	42.3B	39.1B	50.2B	46.9B	53.9B	50.2B
Total Current Assets	30.3B	16.0B	14.8B	14.4B	13.0B	19.1B
Intangible Assets	15.7B	13.8B	33.1B	33.5B	38.5B	24.9B
Property Plant Equipment	5.2B	5.6B	5.7B	6.0B	6.9B	5.4B
Other Current Liab	430M	1.3B	2.3B	1.4B	1.6B	1.3B
Other Liab	6.5B	9.5B	9.6B	7.3B	8.4B	8.8B
Net Tangible Assets	4.6B	(23.0B)	(20.7B)	(16.0B)	(14.4B)	(15.1B)
Accounts Payable	713M	844M	705M	905M	1.0B	870.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Gilead Stock Analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC